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Clinical PerspectiveWhat Is New?Compared with a reference category with high‐density lipoprotein cholesterol (HDL‐C) of 50 to 59 mg/dL, both low (\<30 mg/dL) and high (≥60 mg/dL) HDL‐C levels were associated with an increased risk of disease progression in patients with chronic kidney disease who were not yet undergoing dialysis.The time‐varying Cox analysis and cubic spline model further supported these findings, showing that the association between HDL‐C and adverse renal outcome follows a nonlinear U‐shaped relationship.What Are the Clinical Implications?Both low and high HDL‐C levels could be harmful with respect to chronic kidney disease progression.Our findings support the result of previous studies showing that HDL‐C becomes dysfunctional and even transforms into toxic particles in patients with chronic kidney disease.Future research should focus on the role of the composition and function of HDL in the progression of chronic kidney disease rather than its levels alone.

Introduction {#jah33947-sec-0008}
============

Serum high‐density lipoprotein (HDL) has traditionally been considered to be protective against cardiovascular disease in the general population. HDL exerts an antiatherogenic effect through reverse cholesterol transport, a multiorgan process that removes excess cholesterol from lipid‐laden macrophages and peripheral tissue.[1](#jah33947-bib-0001){ref-type="ref"} In addition, normal HDL also confers protection against atherosclerosis through different mechanisms, including anti‐inflammatory, antioxidative, and antithrombotic effects. The exact mechanisms of these effects are unknown, but previous studies have suggested a possible role of minor HDL components, such as apolipoprotein E, apolipoprotein A‐IV, and apolipoprotein J.[2](#jah33947-bib-0002){ref-type="ref"}, [3](#jah33947-bib-0003){ref-type="ref"}, [4](#jah33947-bib-0004){ref-type="ref"} Not surprisingly, several epidemiologic studies have demonstrated a clear inverse association between serum HDL cholesterol (HDL‐C) and the risk of cardiovascular disease.[5](#jah33947-bib-0005){ref-type="ref"}, [6](#jah33947-bib-0006){ref-type="ref"}, [7](#jah33947-bib-0007){ref-type="ref"} However, recent studies questioned the relevance of HDL‐C as a surrogate marker for HDL‐related cardiovascular risk. Randomized clinical trials that aimed at increasing HDL‐C levels showed no clinical benefit in reducing cardiovascular risk.[8](#jah33947-bib-0008){ref-type="ref"}, [9](#jah33947-bib-0009){ref-type="ref"}, [10](#jah33947-bib-0010){ref-type="ref"} In addition, mendelian randomization analyses failed to show a causal association between genetically elevated HDL‐C levels and risk for myocardial infarction.[11](#jah33947-bib-0011){ref-type="ref"} Furthermore, there is accumulating evidence showing that the composition of HDL determines its functional properties, rather than the levels of circulating HDL‐C.[12](#jah33947-bib-0012){ref-type="ref"} Taken together, these findings raise a concern about the previous notion that high serum HDL‐C levels confer protection against adverse outcomes.

Chronic kidney disease (CKD) has become a serious health concern worldwide, given the high burden of cardiovascular events and death in patients with this condition.[13](#jah33947-bib-0013){ref-type="ref"}, [14](#jah33947-bib-0014){ref-type="ref"} Dyslipidemia is common in patients with CKD and is characterized by lower levels of HDL‐C and higher levels of triglyceride and oxidized low‐density lipoprotein cholesterol.[15](#jah33947-bib-0015){ref-type="ref"} A growing body of evidence suggests that low HDL‐C levels are associated with an increased risk of renal dysfunction in the general population.[16](#jah33947-bib-0016){ref-type="ref"}, [17](#jah33947-bib-0017){ref-type="ref"}, [18](#jah33947-bib-0018){ref-type="ref"}, [19](#jah33947-bib-0019){ref-type="ref"}, [20](#jah33947-bib-0020){ref-type="ref"} However, the relationship between serum HDL‐C levels and disease progression in patients with CKD who are not yet undergoing dialysis has not been fully examined, and previous studies on this issue have shown contradictory results.[21](#jah33947-bib-0021){ref-type="ref"}, [22](#jah33947-bib-0022){ref-type="ref"}, [23](#jah33947-bib-0023){ref-type="ref"}, [24](#jah33947-bib-0024){ref-type="ref"} In addition, these studies were all limited by analyzing only baseline HDL‐C (ie, changes in HDL‐C levels over time were not taken into account). Therefore, the prognostic value of HDL‐C with respect to disease progression in patients with nondialysis CKD remains unclear. Interestingly, in keeping with the aforementioned uncertainty about the protective role of high HDL‐C levels, a recent large‐scale epidemiologic study demonstrated a U‐shaped relationship between serum HDL‐C levels and incident CKD or CKD progression in the general population, in which the risk of adverse renal outcome was increased in the lowest and highest deciles of HDL‐C.[19](#jah33947-bib-0019){ref-type="ref"} In addition, it was found that HDL composition and function is significantly altered in patients with CKD, which leads not only to the loss of its protective properties but also to its transformation into toxic particles.[25](#jah33947-bib-0025){ref-type="ref"} These findings led us to hypothesize that both low and high serum HDL‐C levels have a negative impact on renal function in patients with nondialysis CKD. Therefore, this study aimed to clarify the complex association between serum HDL‐C levels and the risk of CKD progression in a large prospective cohort of patients with CKD.

Materials and Methods {#jah33947-sec-0009}
=====================

Study Design and Participants {#jah33947-sec-0010}
-----------------------------

The KNOW‐CKD (Korean Cohort Study for Outcome in Patients With Chronic Kidney Disease) is a prospective nationwide cohort study investigating various clinical courses and risk factors for the progression of CKD in Korean patients. Patients, aged between 20 and 75 years, with CKD stages from 1 to 5 before dialysis, who voluntarily provided informed consent, were enrolled from 9 tertiary‐care general hospitals throughout Korea between June 2011 and February 2016. The study rationale, design, methods, and protocol summary are provided in detail elsewhere (NCT01630486 at <http://www.clinicaltrials.gov>).[26](#jah33947-bib-0026){ref-type="ref"} Among 2238 patients in the KNOW‐CKD cohort, 70 with missing data of HDL‐C levels were excluded. Finally, 2168 patients were included in the present analysis.

The data that support the findings of this study are available from the KNOW‐CKD investigators on reasonable request. The request can initially be sent to the corresponding author, then will be distributed to the investigators. The relevant data, analytical methods, and study materials will be open to researchers after a comprehensive discussion.

Data Collection and Measurements {#jah33947-sec-0011}
--------------------------------

Demographic details, including age, sex, smoking status, alcohol intake, physical activity, medical history, and comorbid diseases, were obtained from the KNOW‐CKD database. Smoking status was classified as never, former, or current. Alcohol intake was categorized as none, moderate (\<20 g/d), or high (≥20 g/d). The weekly frequency of moderate‐ or vigorous‐intensity physical activity was also investigated. Anthropometric data, including height and weight, were collected at enrollment. Body mass index (BMI) was calculated as initial body weight divided by height squared (kg/m^2^). Blood pressure was measured in the sitting position after subjects had been in a relaxed state for at least 5 minutes, by using an electronic sphygmomanometer. After overnight fasting, blood samples were collected and sent to the central laboratory of KNOW‐CKD (Lab Genomics, Seongnam, Korea) for measurements of creatinine. Other biochemical analyses, including lipid profiles, were done at the local laboratory of each participating center. Most laboratory parameters were measured every 6 months in the first year and annually thereafter, including complete blood cell count, fasting glucose, blood urea nitrogen, creatinine, albumin, calcium, and phosphorus. C‐reactive protein, iron profiles (including total iron‐binding capacity and serum ferritin), and lipid profiles (including triglyceride, HDL‐C, and low‐density lipoprotein cholesterol) were measured repeatedly after 1 year and biennially thereafter. We used a creatinine method that requires calibration traceable to isotope dilution mass spectrometry, and estimated glomerular filtration rate (eGFR) was calculated using the CKD Epidemiologic Collaboration equation.[27](#jah33947-bib-0027){ref-type="ref"} Along with blood samples, urine samples were also immediately sent to the central laboratory for proteinuria measurement. Urine albumin/creatinine ratio was calculated as the urine albumin concentration divided by the urine creatinine concentration (mg/g).

Exposure and Outcome Ascertainment {#jah33947-sec-0012}
----------------------------------

The exposures of interest were baseline and time‐varying serum HDL‐C levels. Given a possible nonlinear relationship with event rates, serum HDL‐C levels were treated as a categorical variable and divided into 5 categories with 10‐mg/dL increments: \<30, 30 to \<40, 40 to \<50, 50 to \<60 (reference), and ≥60 mg/dL. The reference category for each analysis was selected as the fourth group because these groups were the modal categories with the lowest event rates and allowed for the most powerful analyses. We also treated HDL‐C level as a continuous variable and modeled a nonlinear effect by using a restricted cubic spine function.

The primary outcome was a composite of a 50% decline in eGFR from the baseline value or the onset of end‐stage renal disease (ESRD) during the follow‐up period. ESRD was defined as the initiation of renal replacement therapy, including dialysis or renal transplantation. The secondary outcome was the development of ESRD. Patients were followed up until December 31, 2016, and were censored at the date of the last study visit, death, or the studied events.

Statistical Analyses {#jah33947-sec-0013}
--------------------

Cox proportional hazard regression models were separately performed to study the associations of serum HDL‐C levels with subsequent renal outcomes using 2 approaches: (1) fixed models with baseline values were examined to ascertain the association of long‐term exposure with CKD progression, and (2) time‐varying models were assessed to account for changes in exposure over time and to ascertain their short‐term associations.[28](#jah33947-bib-0028){ref-type="ref"} In time‐varying analyses, all laboratory data were incorporated as time‐dependent variables. For each analysis, unadjusted and 2 additional models were constructed on the basis of the level of multivariate adjustment: (1) model 1: unadjusted; (2) model 2: demographic and clinical characteristics of age, sex, study center (Seoul National University Hospital, Seoul National University Bundang Hospital, Yonsei University Severance Hospital, Kangbuk Samsung Medical Center, Seoul St Mary\'s Hospital, Gil Hospital, Eulji General Hospital, Chonnam National University Hospital, or Pusan Paik Hospital), comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), smoking status (former or current versus never), alcohol intake (none versus 1--19 or ≥20 g/d), physical activity (\<3 versus ≥3 times/week), and use of lipid‐modifying drugs (statin, ezetimibe, fibrates, and others); and (3) model 3 (fully adjusted): model 2 plus anthropometric and laboratory parameters, including BMI, systolic blood pressure, serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein, eGFR, and random urine albumin/creatinine ratio. In addition, we explored the continuous, potentially nonlinear relationship between HDL‐C levels and the studied outcomes by using fully adjusted restricted cubic spline models with 4 knots. For sensitivity analysis, we also repeated analyses using HDL‐C categorized into quintiles, where the range of quintiles was \<36, 36 to \<43, 43 to \<50.3, 50.3 to \<60, and ≥60 mg/dL for baseline HDL‐C and \<37, 37 to \<44, 44 to \<51, 51 to \<61, and ≥61 mg/dL for time‐varying HDL‐C values.

To test the robustness of our findings, we then performed subgroup analyses using baseline HDL‐C values, which include age (\<60 versus ≥60 years), sex, diabetic CKD, statin use, BMI (\<25 versus ≥25 kg/m^2^), systolic blood pressure (\<130 versus ≥130 mm Hg), serum albumin concentration (\<4.0 versus ≥4.0 g/dL), C‐reactive protein levels (\<0.6 versus ≥0.6 mg/dL), and eGFR (\<15 versus ≥15 mL/min per 1.73 m^2^) at baseline. All exposure‐event associations were expressed as hazard ratios (HRs) and 95% CIs. Data from descriptive analyses were summarized using means±SD, medians (interquartile ranges), or proportions, as appropriate, and were compared using Student *t* test, ANOVA, Kruskal‐Wallis test, and χ^2^ test. Statistical significance was defined as *P*\<0.05. All statistical analyses were performed using Stata, version 14.2 (Stata Corporation, College Station, TX).

Ethics Statement {#jah33947-sec-0014}
----------------

We performed the study in accordance with the Declaration of Helsinki, and the study protocol was approved by the institutional review board of each participating clinical center (in 2011), as follows: Seoul National University Hospital (1104‐089‐359), Seoul National University Bundang Hospital (B‐1106/129‐008), Yonsei University Severance Hospital (4‐2011‐0163), Kangbuk Samsung Medical Center (2011‐01‐076), Seoul St Mary\'s Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), Eulji General Hospital (201105‐01), Chonnam National University Hospital (CNUH‐2011‐092), and Pusan Paik Hospital (11‐091).

Results {#jah33947-sec-0015}
=======

Baseline Characteristics of the Study Population {#jah33947-sec-0016}
------------------------------------------------

The demographic, clinical, and laboratory characteristics of the patients, according to HDL‐C categories, are presented in Table [1](#jah33947-tbl-0001){ref-type="table"}. Among the 2168 participants, 1335 (61.6%) were men. Their mean±SD age was 53.7±12.2 years, and their mean±SD HDL‐C level was 49.2±15.4 mg/dL. Low (\<40 mg/dL) and high (≥60 mg/dL) HDL‐C levels were observed in 614 patients (28.3%) and 460 patients (21.2%), respectively. Patients with a higher HDL‐C were younger; were more likely to be women and never smokers; and had fewer comorbid conditions, such as diabetes mellitus, hypertension, coronary artery disease, and cerebrovascular disease. In addition, these patients had a lower blood pressure and were less obese and less inflamed than those with a lower HDL‐C. Kidney function was more preserved and the amount of urinary protein excretion was lower in patients with a higher HDL‐C.

###### 

Baseline Characteristics of Patients According to Baseline HDL‐C Levels Categorized Into 5 Groups

  Characteristics                     Total (n=2168)         Baseline Serum HDL‐C Concentrations, mg/dL   *P* Value for Trend                                                                         
  ----------------------------------- ---------------------- -------------------------------------------- ----------------------- ---------------------- --------------------- ---------------------- ---------
  Age, y                              53.7±12.2              57.2±10.8                                    55.7±11.6               54.1±12.1              52.6±12.5             51.4±12.6              \<0.001
  Sex (men), %                        61.6                   80.6                                         77.4                    67.2                   55.1                  38.5                   \<0.001
  Cause of CKD, %                                                                                                                                                                                     
  Glomerulonephritis                  36.2                   16.1                                         30.9                    36.7                   40.1                  41.5                   \<0.001
  Diabetic nephropathy                23.2                   58.1                                         30.9                    24.9                   15.0                  13.3                   \<0.001
  Hypertension                        18.5                   18.3                                         22.6                    20.5                   17.2                  12.2                   \<0.001
  Polycystic kidney disease           16.1                   5.4                                          1.0                     11.0                   22.7                  25.9                   \<0.001
  Others                              6.0                    2.2                                          5.6                     6.9                    5.0                   7.2                    0.237
  Comorbidities, %                                                                                                                                                                                    
  DM                                  33.9                   68.8                                         41.1                    37.0                   24.6                  23.5                   \<0.001
  Hypertension                        96.1                   97.8                                         99.0                    97.3                   95.0                  92.0                   \<0.001
  Coronary artery disease             1.7                    4.3                                          3.1                     1.9                    0.7                   0.2                    \<0.001
  CHF                                 1.5                    2.2                                          1.9                     1.9                    1.3                   0.7                    0.068
  PAOD                                3.6                    4.3                                          4.6                     3.0                    4.1                   2.4                    0.141
  Cerebrovascular disease             6.0                    6.5                                          7.3                     6.0                    7.0                   3.5                    0.043
  Dementia                            0.0                    0.0                                          0.0                     0.2                    0.0                   0.0                    0.556
  COPD                                0.6                    1.1                                          0.4                     1.1                    0.2                   0.2                    0.244
  Connective tissue disease           6.2                    3.2                                          7.7                     6.3                    5.9                   5.4                    0.411
  Peptic ulcer disease                1.8                    1.1                                          1.3                     2.0                    1.3                   2.4                    0.314
  Liver disease                       2.6                    2.2                                          3.3                     3.1                    1.5                   2.4                    0.269
  Smoking status, %                                                                                                                                                                                   
  Never                               53.6                   40.9                                         38.2                    52.5                   59.0                  69.5                   \<0.001
  Former                              30.6                   36.6                                         41.8                    30.4                   26.1                  21.4                   \<0.001
  Current                             15.8                   22.6                                         20.0                    17.0                   14.8                  9.2                    \<0.001
  Alcohol intake, %                                                                                                                                                                                   
  None                                79.5                   83.2                                         79.4                    77.4                   81.3                  77.3                   0.167
  Moderate (1--19 g/d)                8.7                    7.5                                          9.8                     9.8                    8.7                   7.3                    0.681
  High (≥20 g/d)                      11.8                   9.3                                          10.9                    12.8                   9.9                   15.4                   0.035
  Physical activity, %                                                                                                                                                                                
  \<3 Times/wk                        61.8                   63.0                                         64.1                    62.4                   59.3                  60.0                   0.179
  ≥3 Times/wk                         38.2                   37.0                                         35.9                    37.6                   40.7                  40.0                   0.179
  Body mass index, kg/m²              24.6±3.4               25.4±2.8                                     25.4±3.2                25.0±3.3               24.4±3.5              23.2±3.4               \<0.001
  Blood pressure, mm Hg                                                                                                                                                                               
  SBP                                 128.6±16.6             131.1±19.2                                   129.4±17.0              129.0±16.0             127.4±16.0            127.8±16.8             0.017
  DBP                                 76.8±11.2              74.8±13.1                                    76.6±11.1               76.8±10.7              77.2±10.9             76.9±11.8              0.197
  MAP                                 111.3±13.7             112.3±16.0                                   111.8±14.0              111.6±13.2             110.7±13.1            110.8±14.3             0.118
  Antihypertensive agents, %                                                                                                                                                                          
  ACEi                                11.2                   9.7                                          10.4                    12.5                   10.0                  11.7                   0.692
  ARB                                 80.1                   77.4                                         85.4                    80.6                   79.3                  74.6                   \<0.001
  Diuretics                           31.8                   51.6                                         39.8                    34.9                   25.3                  20.9                   \<0.001
  β Blockers                          25.1                   37.9                                         32.1                    29.2                   20.5                  13.5                   \<0.001
  CCB                                 40.9                   57.0                                         48.1                    41.8                   36.8                  32.2                   \<0.001
  Lipid‐modifying agents, %                                                                                                                                                                           
  Statin                              51.9                   52.7                                         54.4                    51.9                   52.1                  48.7                   0.113
  Ezetimibe                           6.5                    8.6                                          7.1                     8.4                    4.1                   5.0                    0.019
  Fibrates                            2.8                    7.5                                          3.1                     2.8                    2.8                   1.3                    0.008
  Other lipid‐modifying drugs         2.4                    3.2                                          3.1                     2.5                    2.4                   1.5                    0.111
  Baseline eGFR, mL/min per 1.73 m²   50.6±30.4              31.2±21.8                                    41.3±24.7               50.0±28.9              54.9±30.8             61.3±34.1              \<0.001
  Lipid parameters, mg/dL                                                                                                                                                                             
  TC                                  174.1±39.1             142.6±33.3                                   162.0±38.3              172.8±37.3             179.1±37.0            191.2±37.1             \<0.001
  LDL‐C                               96.9±31.7              77.3±26.4                                    90.9±30.9               99.9±31.8              100.6±30.9            99.5±31.9              \<0.001
  HDL‐C                               49.2±15.4              26.0±4.5                                     35.0±2.7                44.3±2.8               54.1±2.9              72.0±12.9              \<0.001
  Triglyceride                        157.7±98.6             213.0±119.6                                  199.1±105.1             162.8±93.1             140.9±100.6           109.8±57.8             \<0.001
  Other laboratory parameters                                                                                                                                                                         
  WBC, ×10^3^/μL                      6.6±1.9                7.3±2.2                                      7.1±1.9                 6.7±1.9                6.4±1.8               6.1±1.9                \<0.001
  Fasting glucose, mg/dL              111.1±40.0             117.6±47.1                                   112.8±40.6              113.6±39.9             108.1±38.1            104.3±33.1             \<0.001
  Albumin, g/dL                       4.2±0.4                4.0±0.5                                      4.1±0.4                 4.2±0.4                4.2±0.4               4.2±0.4                0.013
  Calcium, mg/dL                      9.1±0.5                8.8±0.7                                      9.0±0.5                 9.2±0.5                9.2±0.5               9.2±0.6                \<0.001
  Phosphorus, mg/dL                   3.7±0.7                3.8±0.8                                      3.7±0.7                 3.7±0.7                3.6±0.6               3.7±0.7                0.923
  TIBC, mg/dL                         297.8±52.2             276.9±60.5                                   288.6±49.6              300.2±52.3             300.8±50.8            306.3±52.2             \<0.001
  Ferritin, ng/mL                     99.8 (53.9--176.3)     147.3 (71.6--258.4)                          114.6 (65.1--189.4)     108.8 (59.1--186.2)    96.2 (48.9--169.2)    74.7 (37.8--129.0)     \<0.001
  CRP, mg/dL                          0.6 (0.2--1.7)         0.9 (0.5--2.5)                               0.9 (0.3--2.2)          0.7 (0.3--1.8)         0.5 (0.2--1.5)        0.3 (0.1--1.0)         0.001
  UACR, mg/g                          354.1 (77.9--1086.0)   529.1 (119.3--1332.1)                        424.5 (106.1--1264.1)   340.9 (83.4--1095.0)   315.1 (70.1--948.3)   308.4 (50.4--1039.6)   0.046

Values for categorical variables are given as number (percentage); values for continuous variables are given as mean±SD or median (interquartile range). eGFR was calculated using the CKD--Epidemiology Collaboration equation. ACEi indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CRP, C‐reactive protein; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; MAP, mean arterial pressure; PAOD, peripheral arterial occlusive disease; SBP, systolic blood pressure; TC, total cholesterol; TIBC, total iron‐binding capacity; UACR, urine albumin/creatinine ratio; WBC, white blood cell.

HDL‐C and Risk of CKD Progression {#jah33947-sec-0017}
---------------------------------

During a median follow‐up of 3.1 (interquartile range, 1.6--4.5) years, the primary outcome occurred in 335 patients (15.5%). The composite adverse renal outcome occurred most commonly in patients with diabetic nephropathy than in those with other causes of CKD (Table [2](#jah33947-tbl-0002){ref-type="table"}). As expected, more patients with a lower eGFR at baseline reached a ≥50% decline in eGFR, or ESRD (Table [2](#jah33947-tbl-0002){ref-type="table"}). We then evaluated renal outcomes among HDL‐C categories. The primary outcome occurred in 32 (34.4%), 97 (18.6%), 89 (14.0%), 56 (12.2%), and 61 (13.3%) of patients with baseline HDL‐C levels of \<30, 30 to 39, 40 to 49, 50 to 59, and ≥60 mg/dL, respectively (*P*\<0.001) (Table [3](#jah33947-tbl-0003){ref-type="table"}). The unadjusted HRs in the categories of HDL‐C levels of \<30 and ≥60 mg/dL were 3.42 (95% CI, 2.21--5.28) and 1.10 (95% CI, 0.77--1.59), respectively, compared with the category of HDL‐C level of 50 to \<60 mg/dL (model 1). This association was not changed after adjustment for demographic factors, comorbidities, and medications (model 2). However, in a fully adjusted Cox model in which BMI, systolic blood pressure, and laboratory parameters were additionally included, the risk of the composite renal outcome was significantly higher in both the lowest (HR, 2.21; 95% CI, 1.30--3.77) and the highest (HR, 2.05; 95% CI, 1.35--3.10) categories (Table [3](#jah33947-tbl-0003){ref-type="table"}, Figure [1](#jah33947-fig-0001){ref-type="fig"}). The time‐varying analysis consistently showed an increased risk of the composite renal outcome in the groups with HDL‐C levels of \<30 mg/dL (HR, 2.06; 95% CI, 1.18--3.61) and ≥60 mg/dL (HR, 1.62; 95% CI, 1.05--2.52), compared with the reference category (Table [3](#jah33947-tbl-0003){ref-type="table"}, Figure [1](#jah33947-fig-0001){ref-type="fig"}). Restricted cubic spline models with HDL‐C being treated as a continuous variable yielded a similar result (Figure [2](#jah33947-fig-0002){ref-type="fig"}). The association of HDL‐C with the composite renal outcome followed a U‐shaped trend, indicating an increased risk of CKD progression with low and high HDL‐C levels.

###### 

Clinical Outcomes According to Cause of CKD or eGFR Categories

  Outcomes                                      Patients   Renal Outcomes   ≥50% Decline in eGFR   ESRD                      
  --------------------------------------------- ---------- ---------------- ---------------------- ------ ----- ------ ----- ------
  Overall outcome                               2168       100.0            335                    15.5   170   7.8    274   12.6
  Cause of CKD                                                                                                               
  Glomerulonephritis                            784        36.2             87                     11.1   46    5.9    67    8.6
  Diabetic nephropathy                          503        23.2             147                    29.2   62    12.3   128   25.5
  Hypertension                                  400        18.5             42                     10.5   24    6.0    37    9.3
  Polycystic kidney disease                     350        16.1             47                     13.4   30    8.6    33    9.4
  Others                                        131        6.0              12                     9.2    8     6.1    9     6.9
  eGFR categories at T0, mL/min per 1.73 m^2^                                                                                
  ≥90                                           260        12.0             3                      1.2    2     0.8    1     0.4
  \<90--≥60                                     401        18.5             6                      1.5    6     1.5    3     0.8
  \<60--≥45                                     392        18.1             19                     4.9    16    4.1    8     2.0
  \<45--≥30                                     473        21.8             50                     10.6   44    9.3    32    6.8
  \<30--≥15                                     502        23.2             162                    32.3   85    16.9   137   27.3
  \<15                                          140        6.5              95                     67.9   17    12.1   93    66.3

CKD indicates chronic kidney disease; eGFR, estimated glomerular filtration rate; ESRD, end‐stage renal disease; T0, at baseline.

###### 

Association of HDL‐C Levels With Composite Renal Outcome in the Baseline and Time‐Varying Cox Analysis

  HDL‐C Level                 Patient   Event   Model 1   Model 2   Model 3                                                                         
  --------------------------- --------- ------- --------- --------- ------------------- --------- ------------------- --------- ------------------- -------
  Baseline HDL‐C, mg/dL       2168      100.0   335       15.5      ...                 ...       ...                 ...       ...                 ...
  \<30                        93        4.3     32        34.4      3.42 (2.21--5.28)   \<0.001   2.46 (1.56--3.88)   \<0.001   2.21 (1.30--3.77)   0.003
  30--\<40                    521       24.0    97        18.6      1.64 (1.18--2.27)   0.003     1.45 (1.03--2.04)   0.032     1.28 (0.85--1.91)   0.233
  40--\<50                    635       29.3    89        14.0      1.21 (0.87--1.69)   0.261     1.10 (0.78--1.55)   0.585     1.26 (0.86--1.84)   0.242
  50--\<60                    459       21.2    56        12.2      1.00 (Reference)              1.00 (Reference)              1.00 (Reference)    
  ≥60                         460       21.2    61        13.3      1.10 (0.77--1.59)   0.597     1.22 (0.84--1.76)   0.298     2.05 (1.35--3.10)   0.001
  Time‐varying HDL‐C, mg/dL                                                                                                                         
  \<30                        ···       ···     ···       ···       4.57 (2.95--7.09)   \<0.001   3.50 (2.22--5.56)   \<0.001   2.06 (1.18--3.61)   0.011
  30--\<40                    ···       ···     ···       ···       1.92 (1.35--2.72)   \<0.001   1.58 (1.09--2.29)   0.016     1.15 (0.75--1.77)   0.533
  40--\<50                    ···       ···     ···       ···       1.61 (1.14--2.28)   0.007     1.40 (0.98--2.02)   0.068     1.51 (1.01--2.26)   0.045
  50--\<60                    ···       ···     ···       ···       1.00 (Reference)              1.00 (Reference)              1.00 (Reference)    
  ≥60                         ···       ···     ···       ···       1.30 (0.89--1.90)   0.170     1.28 (0.86--1.90)   0.217     1.62 (1.05--2.52)   0.031

Model 1: unadjusted; model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), smoking status (former or current vs never), alcohol intake (none vs 1--19 or ≥20 g/d), physical activity (\<3 vs ≥3 times/week), and lipid‐modifying drugs (statin, ezetimibe, fibrates, and others); model 3: adjusted for model 2 plus body mass index, systolic blood pressure, and laboratory findings (white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein, low‐density lipoprotein cholesterol, triglyceride, estimated glomerular filtration rate, and urine albumin/creatinine ratio). HDL‐C indicates high‐density lipoprotein cholesterol; HR, hazard ratio.

![Associations of baseline (**A**) and time‐varying (**B**) serum high‐density lipoprotein cholesterol (HDL‐C) levels with composite renal outcomes (hazard ratios and 95% CI error bars). Adjustments in model 1: unadjusted; model 2: age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, and use of lipid‐modifying drugs; and model 3: model 2 plus body mass index, systolic blood pressure, serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein level, estimated glomerular filtration rate, and random urine albumin/creatinine ratio.](JAH3-8-e011162-g001){#jah33947-fig-0001}

![Adjusted hazard ratios of composite renal outcomes associated with baseline (**A**) and time‐varying (**B**) serum high‐density lipoprotein cholesterol (HDL‐C) concentrations in a Cox model using restricted cubic spines. All models were adjusted for age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, use of lipid‐modifying drugs, body mass index, systolic blood pressure, serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein level, estimated glomerular filtration rate, and random urine albumin/creatinine ratio.](JAH3-8-e011162-g002){#jah33947-fig-0002}

HDL‐C and Risk of ESRD {#jah33947-sec-0018}
----------------------

The findings from analyses of primary outcome remained unaltered in separate analyses of secondary outcome (development of ESRD). ESRD developed in 30 (32.3%), 81 (15.6%), 71 (11.2%), 41 (8.9%), and 51 (11.1%) of patients with HDL‐C levels of \<30, 30 to 39, 40 to 49, 50 to 59, and ≥60 mg/dL, respectively (*P*\<0.001) (Table [4](#jah33947-tbl-0004){ref-type="table"}). Both groups with low (\<30 mg/dL; HR, 3.42; 95% CI, 1.87--6.27) and high (≥60 mg/dL; HR, 3.24; 95% CI, 2.00--5.27) baseline levels of HDL‐C had a higher risk of ESRD development than the reference group with a baseline HDL‐C level of 50 to 59 mg/dL (Table [4](#jah33947-tbl-0004){ref-type="table"}, Figure [3](#jah33947-fig-0003){ref-type="fig"}). In addition, we observed a similar association between HDL‐C levels and the risk of ESRD in the time‐varying Cox analysis (Table [4](#jah33947-tbl-0004){ref-type="table"}, Figure [3](#jah33947-fig-0003){ref-type="fig"}). A U‐shaped association between HDL‐C level and ESRD development was also found in restricted cubic spline models (Figure [4](#jah33947-fig-0004){ref-type="fig"}).

###### 

Association of HDL‐C Levels With Development of ESRD in the Baseline and Time‐Varying Cox Analysis

  HDL‐C Level                 Patient   Event   Model 1   Model 2   Model 3                                                                         
  --------------------------- --------- ------- --------- --------- ------------------- --------- ------------------- --------- ------------------- ---------
  Baseline HDL‐C, mg/dL       2168      100.0   274       12.6      ...                 ...       ...                 ...       ...                 ...
  \<30                        93        4.3     30        32.3      4.34 (2.71--6.96)   \<0.001   2.98 (1.82--4.89)   \<0.001   3.42 (1.87--6.27)   \<0.001
  30--\<40                    521       24.0    81        15.6      1.87 (1.28--2.72)   0.001     1.62 (1.10--2.38)   0.015     1.69 (1.06--2.71)   0.029
  40--\<50                    635       29.3    71        11.2      1.32 (0.90--1.94)   0.157     1.21 (0.81--1.79)   0.353     1.54 (0.98--2.43)   0.062
  50--\<60                    459       21.2    41        8.9       1.00 (Reference)              1.00 (Reference)              1.00 (Reference)    
  ≥60                         460       21.2    51        11.1      1.26 (0.83--1.89)   0.278     1.47 (0.96--2.24)   0.074     3.24 (2.00--5.27)   \<0.001
  Time‐varying HDL‐C, mg/dL                                                                                                                         
  \<30                        ···       ···     ···       ···       5.89 (3.61--9.61)   \<0.001   4.42 (2.61--7.51)   \<0.001   3.28 (1.71--6.30)   0.001
  30--\<40                    ···       ···     ···       ···       2.43 (1.61--3.66)   \<0.001   1.97 (1.26--3.06)   0.003     1.78 (1.05--3.01)   0.033
  40--\<50                    ···       ···     ···       ···       1.88 (1.24--2.83)   0.003     1.64 (1.06--2.54)   0.027     2.06 (1.24--3.43)   0.005
  50--\<60                    ···       ···     ···       ···       1.00 (Reference)              1.00 (Reference)              1.00 (Reference)    
  ≥60                         ···       ···     ···       ···       1.57 (1.01--2.45)   0.044     1.64 (1.03--2.62)   0.039     2.64 (1.55--4.48)   \<0.001

Model 1: unadjusted; model 2: adjusted for age, sex, study center, comorbidities (diabetes mellitus, hypertension, coronary artery disease, congestive heart failure, peripheral arterial occlusive disease, cerebrovascular disease, dementia, chronic obstructive pulmonary disease, connective tissue disease, peptic ulcer disease, and liver disease), smoking status (former or current vs never), alcohol intake (none vs 1--19 or ≥20 g/d), physical activity (\<3 vs ≥3 times/week), and lipid‐modifying drugs (statin, ezetimibe, fibrates, and others); model 3: adjusted for model 2 plus body mass index, systolic blood pressure, and laboratory findings (white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein, low‐density lipoprotein cholesterol, triglyceride, estimated glomerular filtration rate, and urine albumin/creatinine ratio). ESRD indicates end‐stage renal disease; HDL‐C, high‐density lipoprotein cholesterol; HR, hazard ratio.

![Associations of baseline (**A**) and time‐varying (**B**) serum high‐density lipoprotein cholesterol (HDL‐C) levels with end‐stage renal disease (ESRD; hazard ratios and 95% CI error bars). Adjustments in model 1: unadjusted; model 2: age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, and use of lipid‐modifying drugs; and model 3: model 2 plus body mass index, systolic blood pressure, serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein level, estimated glomerular filtration rate, and random urine albumin/creatinine ratio.](JAH3-8-e011162-g003){#jah33947-fig-0003}

![Adjusted hazard ratios of end‐stage renal disease (ESRD) associated with baseline (**A**) and time‐varying (**B**) serum high‐density lipoprotein cholesterol (HDL‐C) concentrations in a Cox model using restricted cubic spines. All models were adjusted for age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, use of lipid‐modifying drugs, body mass index, systolic blood pressure, serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein level, estimated glomerular filtration rate, and random urine albumin/creatinine ratio.](JAH3-8-e011162-g004){#jah33947-fig-0004}

Subgroup Analyses {#jah33947-sec-0019}
-----------------

The results of subgroup analyses are shown in Figure [5](#jah33947-fig-0005){ref-type="fig"}. A significant association of low baseline HDL‐C (\<30 mg/dL) with CKD progression was evident particularly in men; in those with a lower BMI (\<25 kg/m^2^) and systolic blood pressure (\<130 mm Hg); and in those with higher albumin (≥4.0 g/dL) and C‐reactive protein (≥0.6 mg/dL) levels (Figure [5](#jah33947-fig-0005){ref-type="fig"}A). On the other hand, there was a consistent trend of the impact of baseline high HDL‐C with respect to CKD progression in most of the stratified groups (Figure [5](#jah33947-fig-0005){ref-type="fig"}B).

![Adjusted hazard ratios (and 95% CI error bars) of composite renal outcomes for the low (\<30 mg/dL; **A**) and high (≥60 mg/dL; **B**) high‐density lipoprotein cholesterol (HDL‐C) categories vs the reference group (30--\<60 mg/dL) of baseline HDL‐C levels in various subgroups. All models were adjusted for age, sex, study center, comorbidities, smoking status, alcohol intake, physical activity, use of lipid‐modifying drugs, body mass index (BMI), systolic blood pressure (SBP), serum low‐density lipoprotein cholesterol, triglyceride, white blood cell count, fasting glucose, albumin, calcium, phosphorus, total iron‐binding capacity, ferritin, C‐reactive protein (CRP) level, estimated glomerular filtration rate (eGFR), and urine albumin/creatinine ratio. CKD indicates chronic kidney disease.](JAH3-8-e011162-g005){#jah33947-fig-0005}

Sensitivity Analyses {#jah33947-sec-0020}
--------------------

To test the robustness and consistency of our findings, we conducted a sensitivity analysis in which participants were recategorized according to quintiles of HDL‐C. The risk of the composite renal outcome was significantly higher in both the first (HR, 1.56; 95% CI, 1.01--2.39) and fifth (HR, 2.11; 95% CI, 1.38--3.24) quintiles compared with the fourth quintile of baseline HDL‐C (Table [S1](#jah33947-sup-0001){ref-type="supplementary-material"}, Figure [S1](#jah33947-sup-0001){ref-type="supplementary-material"}). The time‐varying Cox analysis showed that the fifth quintile of HDL‐C (HR, 1.61; 95% CI, 1.02--2.52) had a higher risk of the composite renal outcome than the fourth quintile, whereas the risk of the composite renal outcome was not significantly different in the first quintile of HDL‐C (HR, 1.32; 95% CI, 0.85--2.06). Similar results were obtained in the secondary outcome analyses for the development of ESRD (Table [S2](#jah33947-sup-0001){ref-type="supplementary-material"}, Figure [S2](#jah33947-sup-0001){ref-type="supplementary-material"}). The risk of ESRD was higher in both the first (HR, 2.05; 95% CI, 1.24--3.41) and fifth (HR, 3.52; 95% CI, 2.13--5.82) quintiles of HDL‐C than the fourth quintile of baseline HDL‐C. This association remained unaltered in a time‐varying Cox analysis.

Discussion {#jah33947-sec-0021}
==========

In this large, prospective, cohort study, we showed that, compared with a reference category with HDL‐C of 50 to 59 mg/dL, both low (\<30 mg/dL) and high (≥60 mg/dL) HDL‐C levels were associated with an increased risk of disease progression in patients with CKD who were not yet undergoing dialysis. The time‐varying Cox analysis and cubic spline model further supported these findings, showing that the association between HDL‐C and adverse renal outcome follows a nonlinear U‐shaped relationship. Our findings suggest that both low and high HDL‐C levels may contribute to the progression of CKD in patients not yet undergoing dialysis.

Low HDL‐C is a traditional risk factor for future cardiovascular events.[7](#jah33947-bib-0007){ref-type="ref"} In line with this, several epidemiologic studies have suggested an association between low HDL‐C and poor renal function in the general population.[16](#jah33947-bib-0016){ref-type="ref"}, [17](#jah33947-bib-0017){ref-type="ref"}, [18](#jah33947-bib-0018){ref-type="ref"}, [19](#jah33947-bib-0019){ref-type="ref"}, [20](#jah33947-bib-0020){ref-type="ref"} Low HDL‐C predicted an increased risk of renal dysfunction in 12 728 participants from the ARIC (Atherosclerosis Risk in Communities) cohort study with baseline serum creatinine of \<2.0 mg/dL in men and \<1.8 mg/dL in women.[16](#jah33947-bib-0016){ref-type="ref"} More recently, Bowe et al also showed a significant relationship between low levels of HDL‐C and an increased risk of incident CKD and its progression in a cohort of almost 2 million male veterans over a median follow‐up of 9 years.[19](#jah33947-bib-0019){ref-type="ref"} Notably, there was a U‐shaped relationship between HDL‐C level and the future development of CKD in this study, and high HDL‐C level was also associated with adverse renal outcomes. However, it is unclear whether these findings can be extrapolated to the whole CKD population because this study included only white elderly veteran men who had normal kidney function (eGFR, \>60 mL/min per 1.73 m^2^) at study initiation.

To date, studies on the relationship between HDL‐C levels and adverse renal outcome in nondialysis patients with CKD are scarce and have shown conflicting results.[21](#jah33947-bib-0021){ref-type="ref"}, [22](#jah33947-bib-0022){ref-type="ref"}, [23](#jah33947-bib-0023){ref-type="ref"}, [24](#jah33947-bib-0024){ref-type="ref"} Baragetti et al showed that low HDL‐C levels were associated with earlier entry to a dialysis program or doubling of the plasma creatinine levels in 176 patients with CKD.[23](#jah33947-bib-0023){ref-type="ref"} In addition, the MDRD (Modification of Diet in Renal Disease) Study revealed that lower HDL‐C independently predicted a faster decline in kidney function in 840 patients with diverse renal diseases.[22](#jah33947-bib-0022){ref-type="ref"} In contrast, a recent publication by the CRIC (Chronic Renal Insufficiency Cohort) study investigators showed that HDL‐C was not independently associated with the composite end point of ESRD or a 50% reduction in eGFR in 3939 adults with CKD.[24](#jah33947-bib-0024){ref-type="ref"} However, HR was determined per 1‐SD increase of HDL‐C; thus, the insignificant results of the study might be attributable to an inability to distinguish the nonlinear associations among HDL‐C categories. Moreover, all the previous studies were limited by analyzing only the baseline HDL‐C levels. Our study sought to overcome the limitations of previous studies by analyzing both the baseline HDL‐C measurements and the HDL‐C changes during the follow‐up period in a large cohort of patients with CKD. In this regard, our findings provide robust evidence that both low and high HDL‐C levels were associated with an increased risk of CKD progression in patients with nondialysis CKD.

CKD has an impact on serum HDL‐C levels that is determined by the rate of HDL‐mediated reverse cholesterol uptake from peripheral tissues and unloading of its cholesterol cargo in the liver.[29](#jah33947-bib-0029){ref-type="ref"} HDL‐mediated reverse cholesterol uptake is significantly impaired in chronic inflammatory and oxidative stress conditions, such as CKD.[30](#jah33947-bib-0030){ref-type="ref"} Reduced production and increased catabolism of apolipoprotein A1, downregulation of lecithin‐cholesterol acyltransferase, and upregulation of acyl--coenzyme A cholesterol acyltransferase‐1 can contribute to the defective HDL‐mediated cholesterol uptake in CKD.[31](#jah33947-bib-0031){ref-type="ref"} In addition, modification of apolipoprotein A1 by reactive oxygen species (oxidation), elevated urea level (carbamylation), and systemic inflammation (myeloperoxidase modification) impairs the ability of HDL to bind to the machinery mediating cholesterol efflux via ATP‐binding cassette transporter A1 and G1.[32](#jah33947-bib-0032){ref-type="ref"} Furthermore, the unloading of HDL‐C cargo is also impaired in CKD. The aforementioned modifications may limit the binding of HDL to scavenger receptor‐B1, leading to defective disposal of HDL‐C cargo in the liver.[33](#jah33947-bib-0033){ref-type="ref"} Advanced oxidation protein products, which are carried by oxidized plasma protein and accumulate in renal disease,[34](#jah33947-bib-0034){ref-type="ref"} also bind to scavenger receptor‐B1 with high affinity and further prevent cholesterol influx.[25](#jah33947-bib-0025){ref-type="ref"} Taken together, reverse cholesterol transport properties are defective in the patients with CKD because both HDL‐mediated reverse cholesterol uptake and unloading capacity of its cholesterol cargo are impaired. However, their effects on HDL‐C levels are opposite: impaired cholesterol uptake from peripheral tissues leads to HDL‐C deficiency, whereas compromised HDL‐C unloading capacity increases serum HDL‐C levels. In this regard, high HDL‐C in CKD might, in part, indicate defective reverse cholesterol transport, rather than improved HDL function.

Although HDL‐C levels are affected by CKD itself, our study showed that both low and high HDL‐C levels could be harmful with respect to CKD progression, suggesting a bidirectional association between 2 factors. Nevertheless, it is still unclear whether low HDL‐C is causally linked to the progression of CKD. In addition to the altered HDL metabolism in CKD, low HDL‐C levels might be attributed to poor overall metabolic health, which can contribute to the decline in kidney function.[35](#jah33947-bib-0035){ref-type="ref"} In fact, some genetic studies and randomized clinical trials suggested that low HDL‐C might simply be a marker reflecting residual risk rather than an independent driver of adverse outcomes.[8](#jah33947-bib-0008){ref-type="ref"}, [9](#jah33947-bib-0009){ref-type="ref"}, [10](#jah33947-bib-0010){ref-type="ref"}, [36](#jah33947-bib-0036){ref-type="ref"} For instance, Coassin et al revealed that the genetic variants having the strongest associations with HDL‐C levels were not related to kidney function.[36](#jah33947-bib-0036){ref-type="ref"} In addition, pharmacologic agents that increase serum HDL‐C, such as niacin and cholesterol ester transfer protein inhibitors, had no effect on cardiovascular events and renal function in randomized clinical trials.[8](#jah33947-bib-0008){ref-type="ref"}, [9](#jah33947-bib-0009){ref-type="ref"}, [10](#jah33947-bib-0010){ref-type="ref"} However, we clearly showed an independent association of low HDL‐C with CKD progression, even after a rigorous adjustment for multiple confounding factors. Our findings are supported by experimental studies demonstrating that HDL‐C deficiency or dysfunction induced renal vascular atherosclerosis and glomerular and tubulointerstitial injury.[37](#jah33947-bib-0037){ref-type="ref"}, [38](#jah33947-bib-0038){ref-type="ref"}, [39](#jah33947-bib-0039){ref-type="ref"} Furthermore, a recent mendelian randomization study suggested a small, but robust, causal association between HDL‐C concentration and eGFR in the general population.[32](#jah33947-bib-0032){ref-type="ref"} These findings together raise the possibility of a causal association between low HDL‐C and renal dysfunction.

The association between HDL‐C and the risk of adverse renal outcome follows a U‐shaped curve, suggesting that high HDL‐C could also be harmful with respect to CKD progression. Several studies can explain the possible mechanisms responsible for this phenomenon. An experimental study by Huang et al showed that moderate to high concentrations of HDL in healthy subjects paradoxically impaired endothelial progenitor cells and angiogenesis in the absence of oxidized low‐density lipoprotein, suggesting the biphasic effects of HDL.[40](#jah33947-bib-0040){ref-type="ref"} In addition, accumulating evidence shows that inflammation and oxidative stress can impair reverse cholesterol transport and reduce the anti‐inflammatory and antioxidant properties of HDL.[41](#jah33947-bib-0041){ref-type="ref"} Interestingly, CKD involves a high level of inflammation accompanied by a high burden of oxidative stress,[42](#jah33947-bib-0042){ref-type="ref"} and the antioxidant and anti‐inflammatory activity of HDL is diminished in patients with CKD.[43](#jah33947-bib-0043){ref-type="ref"}, [44](#jah33947-bib-0044){ref-type="ref"}, [45](#jah33947-bib-0045){ref-type="ref"} A reduced activity of HDL‐associated antioxidant enzymes, such as paraoxonase‐1, glutathione peroxidase, and lecithin‐cholesterol acyltransferase, can contribute to these findings in CKD.[31](#jah33947-bib-0031){ref-type="ref"} Furthermore, HDL can transform into the opposite pro‐oxidant and proinflammatory directions in CKD.[44](#jah33947-bib-0044){ref-type="ref"}, [46](#jah33947-bib-0046){ref-type="ref"} This was demonstrated by Speer et al, who showed that HDL in patients with CKD reduced endothelial NO availability via toll‐like receptor‐2, leading to impaired endothelial repair, increased proinflammatory activation, and increased blood pressure.[47](#jah33947-bib-0047){ref-type="ref"} This transformation can be facilitated by the oxidative modification of apolipoprotein A1 and other components of HDL and the accumulation of proinflammatory proteins, such as serum amyloid‐A, which promote cytokine production and increase the endothelial production of reactive oxygen species.[31](#jah33947-bib-0031){ref-type="ref"}, [48](#jah33947-bib-0048){ref-type="ref"} In accordance with these findings, several observational studies showed paradoxical associations between elevated HDL‐C levels and cardiovascular events or mortality in certain conditions with chronic inflammation, particularly in patients undergoing hemodialysis.[29](#jah33947-bib-0029){ref-type="ref"}, [49](#jah33947-bib-0049){ref-type="ref"}, [50](#jah33947-bib-0050){ref-type="ref"}, [51](#jah33947-bib-0051){ref-type="ref"} Therefore, it can be presumed that high levels of toxic HDL particles in CKD might contribute to adverse outcomes, including deterioration of kidney function.

Several shortcomings of this study should be considered. First, given the observational nature of the study, it is possible that potential confounding factors were not entirely controlled. However, this study included a large number of participants and analyzed the data by using various multivariable Cox models after a rigorous adjustment for measured covariates. Second, most of the patients in our study had relatively preserved kidney function; thus, the association between HDL‐C and CKD progression needs to be verified in patients with advanced stages of CKD. However, the results of subgroup analysis by baseline eGFR were consistent with the main findings, and a significant association was also seen in patients with advanced CKD. Third, HDL‐C levels were measured at the local laboratory of each participating center, not the central laboratory. This could raise a concern about imprecision and bias among various methods for measuring HLD‐C.[52](#jah33947-bib-0052){ref-type="ref"} However, all laboratories in our study used the same direct enzymatic assay for the measurement. In addition, to mitigate bias associated with the center effect, this was adjusted in the multivariable model and the results were consistent. Fourth, we did not conduct a qualitative assessment of HDL‐C composition and function, or HDL‐C subclasses. As aforementioned, some researchers have suggested the importance of alterations in the composition and function of HDL‐C, rather than the quantity of HDL‐C. Nevertheless, we clearly showed the biphasic association of HDL‐C with adverse renal outcome by using various statistical models and suggested that quantitative assessment can also explain the complex role of HDL‐C in patients with CKD. Finally, as the event rates for cardiovascular disease or mortality were low because of the relatively short duration of follow‐up, we did not investigate the relationship between HDL‐C and cardiovascular events or mortality. Future reports from the KNOW‐CKD will focus on these issues.

In conclusion, both low and high HDL‐C levels were associated with an increased risk of disease progression in patients with nondialysis CKD, showing a nonlinear U‐shaped relationship. Our findings support the results of previous studies showing that HDL‐C becomes dysfunctional and even transforms into toxic particles in patients with CKD. Future research should focus on the role of the composition and function of HDL in the progression of CKD, rather than its levels alone.
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**Table S2.** Association of Quintiles of High‐Density Cholesterol Levels With Development of ESRD in the Baseline and Time‐Varying Cox Analyses

**Figure S1.** Association of quintiles of high‐density cholesterol levels with composite renal outcome in the (**A**) baseline and (**B**) time‐varying Cox analyses (hazard ratios and 95% confidence interval error bars).

**Figure S2.** Association of quintiles of high‐density cholesterol levels with end‐stage renal disease in the (**A**) baseline and (**B**) time‐varying Cox analyses (hazard ratios and 95% confidence interval error bars).
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